MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid t… Read more
MorphoSys AG (MPSYF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: 0.246x
Based on the latest financial reports, MorphoSys AG (MPSYF) has a cash flow conversion efficiency ratio of 0.246x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-64.43 Million) by net assets ($-261.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MorphoSys AG - Cash Flow Conversion Efficiency Trend (2002–2023)
This chart illustrates how MorphoSys AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MorphoSys AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MorphoSys AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGUIA RES LTD AD-20
F:5N91
|
N/A |
|
Tasco Bhd
KLSE:5140
|
0.075x |
|
ENERGIA IN.Y DES. EO 025
F:F63
|
N/A |
|
APEX Wind Power Equipment Manufacturing
TWO:7702
|
-0.916x |
|
Lii Hen Industries Bhd
KLSE:7089
|
0.033x |
|
VULCAN MINLS
F:VM3
|
N/A |
|
HIPAY GROUP INH. EO 4-
F:9LH
|
N/A |
|
Anxo Pharmaceutical Co., Ltd.
TWO:6677
|
-0.011x |
Annual Cash Flow Conversion Efficiency for MorphoSys AG (2002–2023)
The table below shows the annual cash flow conversion efficiency of MorphoSys AG from 2002 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $49.05 Million | $-295.84 Million | -6.031x | -158.90% |
| 2022-12-31 | $157.41 Million | $-366.71 Million | -2.330x | -18.49% |
| 2021-12-31 | $244.88 Million | $-481.45 Million | -1.966x | -3563.50% |
| 2020-12-31 | $621.32 Million | $35.27 Million | 0.057x | +127.96% |
| 2019-12-31 | $394.70 Million | $-80.14 Million | -0.203x | -198.04% |
| 2018-12-31 | $488.37 Million | $-33.27 Million | -0.068x | +36.45% |
| 2017-12-31 | $358.67 Million | $-38.45 Million | -0.107x | +4.47% |
| 2016-12-31 | $415.46 Million | $-46.62 Million | -0.112x | -73.09% |
| 2015-12-31 | $362.74 Million | $-23.51 Million | -0.065x | -59.02% |
| 2014-12-31 | $348.80 Million | $-14.22 Million | -0.041x | -116.10% |
| 2013-12-31 | $352.15 Million | $89.14 Million | 0.253x | +2756.64% |
| 2012-12-31 | $202.01 Million | $1.79 Million | 0.009x | -93.55% |
| 2011-12-31 | $197.14 Million | $27.07 Million | 0.137x | +908.29% |
| 2010-12-31 | $185.92 Million | $2.53 Million | 0.014x | +341.96% |
| 2009-12-31 | $173.93 Million | $-979.03K | -0.006x | -103.18% |
| 2008-12-31 | $161.99 Million | $28.65 Million | 0.177x | +52.70% |
| 2007-12-31 | $145.54 Million | $16.86 Million | 0.116x | -24.94% |
| 2006-12-31 | $100.05 Million | $15.44 Million | 0.154x | +134.24% |
| 2005-12-31 | $64.01 Million | $4.22 Million | 0.066x | -44.53% |
| 2004-12-31 | $39.38 Million | $4.68 Million | 0.119x | -38.34% |
| 2003-12-31 | $30.18 Million | $5.81 Million | 0.193x | +126.04% |
| 2002-12-31 | $20.62 Million | $-15.25 Million | -0.740x | -- |